New Delhi: Union Health Minister Dr Harsh Vardhan inaugurated India’s first pneumococcal conjugate vaccine, “Pneumosil”, which has been developed by the Serum Institute of India. The vaccine would assist in stopping about 67,800 little one mortality below 5 years of age in India from pneumococcal ailments yearly.
The vaccine is developed by the Serum Institute of India (SII) in collaboration the Bill and Melinda Gates Foundation. Pneumococcal illness is a major contributor to the under-five mortality fee worldwide.
Speaking in regards to the launch, Dr Harsh Vardhan on Monday (December 28) referred to as it as a step in direction of Atmanirbhar Bharat, and added that India was fully depending on PCV manufactured by overseas producers which can be found at very excessive costs.
Dr Harsh Vardhan, mentioned, “It is a great moment of pride to witness Serum Institute take forward the `Make in India` legacy, with the launch of India`s first indigenously developed Pneumococcal Conjugate Vaccine. It is a significant milestone for the country`s public health care which will ensure that children are protected better against Pneumococcal disease with an affordable and high-quality vaccine.”
“I am sure, Serum Institute of India will continue their endeavour to develop many more life-saving vaccines in the future also on the lines of the clarion call of our Hon`ble Prime Minister “VOCAL FOR LOCAL” and fulfill our Hon`ble Prime Minister`s dream `ATMANIRBHARBHARAT`,” he added.
Union Health Minister mentioned, “It is a matter of great pride for us that the pharma major developed the first indigenous vaccine and got a license for the same from Central government during COVID-19 pandemic lock-down period. Pneumonia is the single largest infectious cause of death among children under five years of age worldwide, accounting for nearly 10 lakhs deaths globally.”
He mentioned, “Pneumosil has been extensively evaluated in 5 randomised controlled clinical trials and has demonstrated comparable safety and immunogenicity against licensed pneumococcal vaccines across diverse populations of India and Africa, where Pneumosil was administered to adults, toddlers and infants using different vaccination schedules.”
During medical trials, Pneumosil was discovered to be secure and efficient within the prevention of pneumonia illness and based mostly on which Pneumosil has been licensed by Drugs Controller General (India) in July 2020 after approval from Subject Expert Committee (SEC), the Union Minister mentioned.
Adar Poonawalla, CEO of SII, advised reporters through on-line convention, “Over the years, we have been constantly working to provide high-quality vaccines to ensure excellent immunisation coverage to children and families worldwide.”
“Now, we have developed this PCV with a unique composition based on the serotype prevalence in India. This makes our PCV an ideal choice for protecting our children from pneumococcal disease. While the vaccine itself is of the highest quality and grade available, vaccine accessibility is of utmost importance as well, and to ensure ease of access by making it available at an affordable price. We hope to bring down the mortality rate significantly while also making our country self-sufficient with a robust public health care system,” he added.
In 2018, recognising the illness widespread fatality, the World Health Organisation (WHO) really useful the inclusion of PCV in routine childhood immunisation applications in all nations.
Serum Institute of India, the most important vaccine producer on the earth by doses, broadcasts the launch of India`s first indigenously developed pneumococcal vaccine – PNEUMOSIL, within the presence of Dr Harsh Vardhan, Minister of Health and Family Welfare on Monday.
PNEUMOSIL has been developed by means of a collaboration spanning over a decade amongst Serum Institute of India Pvt Ltd, PATH and Bill and Melinda Gates Foundation. This is aimed toward bettering pneumococcal conjugate vaccine affordability and enabling sustainable entry for low-and middle-income nations, learn a press assertion.
The vaccine will present efficient and long-lasting safety for youngsters towards pneumococcal ailments. With this, SII additional cements its place because the chief within the conjugate vaccines.
(With Agency Inputs)